---

Background: Pyelonephrities is the urinary tract infection. Using supplemental dugs may decrease duration of treatment and hospitalization. We studied the effect of vitamin C on the recovery of symptoms due to pyelonephrities Methods and Materials: In this clinical trial, double blind, study, 64 patients with uncomplicated pyelonephrities were assessed in 2 groups randomly. Case group took vitamin C capsules, and control group took placebo capsules. In both groups, primary treatment was ceftriaxon capsules during hospitalization and they took ciprofloxacin capsules for 14 days after discharging. Symptoms and Urinary analysis were assessed in the first day of administration and then on the 7th and 14th days after discharging. Data were analyzed with Chi-Square test. Results: Mean of fever duration in vitamin C group (1.130.34 SD day) and placebo group (1.560.62 SD day) significantly decrease (p=0.001). There was a significant difference in dysuria duration in vitamin C group 2.191.06 SD day with placebo group (2.971.06 SD day) (p =0.007). In flank pain, nausea and vomiting duration difference was not significantly (p≥ 0.05). Conclusion: It seems vitamin C, as a supplemental drug improves some pyelonephrities symptoms, such as fever and dysuria, decreases of the hospitalization period

---

Background: Shigella dysenteriae one of the main causes of diarrhea in humans, but there is no vaccine against it. IpaD protein is one of the most important virulence factors in pathogenic shigella. The cloning N-terminal ipaD genes with ctB genes that have a role in adjuvant and carrier as recombinant vaccine can caused enhance the mucosal immune response.

Materials and Methods: Designing primers for genes ctB and ipaD were carried out based on the construction of gene cassettes, respectively. PCR reactions were performed to amplify the fragments and amplified fragments were cloned into pGEM-Teasy vector. Both the vector cut by restriction enzymes HindIII and XhoI and ipaD gene to gene ctB finally were Fusion. The ctB-ipaD gene cassette and expression vector pET28a(+) cuted by SalI and HindIII restriction enzymes. The cloning ctB-ipaD cassette was performed in the expression vector and expression of gene cassettes.

Results: In this study, the N-terminal ipaD as vaccine candidate antigen was genetically linked to the C terminal of ctB which has a carrier and adjuvant role. Fusing ctB-ipaD in the expression vector pET28a(+) is confirmed by sequencing, PCR and digested with restriction enzymes. The recombinant proteins produced is confirmed by SDS-PAGE and Western blot.

Conclusion: According to previous and similar studies, product cassette ctB-ipaD and expression its was expected. Is hoped to protein expression of this gene cassette and the production of antibodies could be achieved the candidate vaccine against Shigella.

---

Background: The outbreaks of new antigenic variants of influenza viruses in human populations have increased necessity the improvement of controlling programs. Influenza vaccines are formulated with adjuvant to enhance and direct the host immune responses. Currently, much effort is devoted to designing molecular adjutants. Hemokinin-1 (HK-1) activates T and B cells for proliferation, survival, differentiation into plasma cells, and antibody production. In this study, the effect of HK-1 as a molecular adjuvant for inducing humoral immune response against influenza virus was investigated.

Materials and Methods: The HK-1 coding sequence was cloned into pcDNA3.1 vector and used as adjuvant. Groups of mice were immunized with an inactivated influenza vaccine formulated with HK-1. The sera of vaccinated mice were collected prior to priming and boosting injections and at defined weeks, and analyzed with serological assays.

Results: The results showed that HK-1 was able to increase antibody titer against virus vaccine. The mice immunized with the adjuvanted vaccine produced higher antibody titers against influenza comparing to vaccine alone immunized group. Number of boosting had no effect on the enhancing of antibody titer.

Conclusion: These data revealed that HK-1 as a molecular adjuvant induces stronger humoral and memory responses against influenza immunization.

---

Background: The emergence of antibiotic resistance, particularly resistance to methicillin in Staphylococcus aureus has made the treatment process more difficult. Therefore, producing of an effective vaccine seems to be necessary to prevent infections with methicillin-resistant Staphylococcus aureus (MRSA). In this study, a mixture of naloxone and alum has been used to improve the efficacy of a vaccine against MRSA.

Materials and Methods: MRSA 834 strain was grown on TSB medium and the grown cells were harvested and killed by sonication and were used as a vaccine model. Balb/c mice were divided into six groups and the vaccines were either injected alone, with naloxone, alum, or a mixture of naloxone - alum and control group received naloxone and PBS buffer. Total IgG antibody level was measured by ELISA method and finally, the challenge test of this bacterium was performed and the mice were examined regarding the degree of bacteria growth in their kidneys.

Results: The serum level of Total IgG antibody in the mixture of naloxone – alum with MRSA group was shown to be significantly increased (p<0.05). Furthermore, the lowest bacterial load was observed in this group.

Conclusion: It seems that a mixture of naloxone and alum as an adjuvant with the killed methicillin-resistant Staphylococcus aureus enhances the humoral immunity leading to a high level of protection against MRSA infections. Therefore, this seems to be a good option for improving the performance of this vaccine.

---

Background: Influenza A viruses are globally important respiratory pathogens which cause a high degree of morbidity and mortality during annual epidemics. M2 protein which expressed on the viral surface facilitates virus entry to the host cells. The extracellular domain of M2 protein (M2e) consists of N-terminal 24 residue which shows remarkable conservation among all subtypes of influenza A viruses. In this study, we evaluated the immunogenicity of three tandem repeats of M2e along with different adjuvants in BALB/C mice model.

Materials and Methods: Recombinant protein (3M2e) was expressed in Escherichia coli and purified. Six weeks old BALB/c mice were immunized interdermally with three doses of 3M2e alone or supplemented with Alum/CpG motif as adjuvant. Control group was injected with PBS. Two weeks after the last immunization, specific anti-M2 was measured using ELISA method and finally mice were challenged with one lethal dose (LD90) of PR8 virus.

Results: The results showed that 3M2e can induce specific antibody alone. However, 3M2e protein supplemented with Alum-CpG induced higher level of specific antibodies, so that, there was a significant difference with 3M2e group (p<0.05). Anti-M2 antibodies mostly consisted of IgG2a subclass which considered as activity index of TH1 Cells. Moreover, this group showed enhanced protection against wild-type virus (survival rate=60%).

Conclusion: Applying Alum-CpG as a complex adjuvant may play a crucial role in integrating innate and acquisitive immunity. We increased density of M2e in combination with complex adjuvant and showed that this vaccine induced power immune responses and semi-protected mice against lethal challenge.